Durvalumab and Tremelimumab in Treating Patients with Somatically Hypermutated Recurrent or Refractory Solid Tumors

Status: Active

Description

This phase II trial studies how well durvalumab works in combination with tremelimumab in treating patients with somatically hypermutated solid tumors that have come back or have not responded to treatment. Somatic hypermutation is a cellular mechanism that happens when the immune system adapts to a new foreign element (e.g. microbes). Immunotherapy with monoclonal antibodies, such as durvalumab and tremelimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving durvalumab with tremelimumab may work better in treating patients with somatically hypermutated solid tumors compared to standard treatment (chemotherapy, immunotherapy [using your immune system to treat your cancer] with other agents, or palliative care [no treatment]).

Eligibility Criteria

Inclusion Criteria

  • Relapsed/refractory solid tumor patients not previously treated with anti–PD-1/PD-L1 or anti–CTLA-4 immunotherapy whose tumors expressed a high tumor mutational burden (TMB) (TMB high >= 20 mutations/MB) or moderate TMB (10 to 19 mutations/MB) as based on next generation sequencing (NGS)
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 and life expectancy greater than 3 months
  • Accurate documentation of date of starting previous therapy and date of progression (imaging study confirming progression) to establish TTP from most recent therapy
  • Absolute neutrophil count (ANC) >= 1.0 k/uL (independent of transfusion for at least 7 days prior to screening and independent of growth factor support for at least 14 days prior to screening)
  • Platelet count >= 75 k/uL (independent of transfusion for at least 7 days prior to screening and independent of growth factor support for at least 14 days prior to screening)
  • Serum bilirubin =< 1.5 x institutional upper limit of normal (ULN) (independent of transfusion for at least 7 days prior to screening and independent of growth factor support for at least 14 days prior to screening). This will not apply to patients with confirmed Gilbert’s syndrome, who will be allowed only in consultation with their physician
  • Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x institutional upper limit of normal unless liver metastases are present, in which case it must be =< 5 x ULN (independent of transfusion for at least 7 days prior to screening and independent of growth factor support for at least 14 days prior to screening)
  • Measured creatinine clearance (CL) > 40 mL/min or calculated creatinine clearance CL > 40 mL/min by the Cockcroft-Gault formula (Cockcroft and Gault 1976) or by 24-hour urine collection for determination of creatinine clearance (independent of transfusion for at least 7 days prior to screening and independent of growth factor support for at least 14 days prior to screening)
  • The effects of MEDI4736 and tremelimumab on the developing human fetus are unknown. Evidence of postmenopausal status or negative urinary or serum pregnancy test for female pre-menopausal patients. Women will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply: * Women < 50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution or underwent surgical sterilization (bilateral oophorectomy or hysterectomy) * Women >= 50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments, had radiation-induced menopause with last menses > 1 year ago, had chemotherapy-induced menopause with last menses > 1 year ago, or underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy or hysterectomy) * Females of childbearing potential who are sexually active with a non-sterilized male partner must use at least 1 highly effective method of contraception from the time of screening and must agree to continue using such precaution for 180 days after the last dose of durvalumab + tremelimumab combination therapy or 90 days after the last dose of durvalumab monotherapy. Non-sterilized male partners of female patient must use male condom plus spermicide throughout this period. Cessation of birth control after this point should be discussed with a responsible physician. Not engaging in sexual activity for the total duration of the drug treatment and the drug washout period is an acceptable practice; however, periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of birth control. Female patients should also refrain from breastfeeding throughout this period * Non-sterilized males who are sexually active with a female partner of childbearing potential must use a male condom plus spermicide from screening through 180 days after receipt of the final dose of durvalumab + tremelimumab combination therapy or 90 days after receipt of the final dose of durvalumab monotherapy. Not engaging in sexual activity is an acceptable practice; however, occasional abstinence, the rhythm method, and the withdrawal method are not acceptable methods of contraception. Male patients should refrain from sperm donation throughout this period
  • Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up
  • Body weight > 30 kg
  • Available archival tumor sample taken less than 12 months prior to study enrollment

Exclusion Criteria

  • Lung, head and neck squamous cell carcinoma, bladder, or melanoma primary cancer diagnosis
  • Receipt of the last dose of anticancer therapy (chemotherapy, immunotherapy, endocrine therapy, targeted therapy, biologic therapy, tumor embolization, monoclonal antibodies) 30 days prior to the first dose of study drug
  • Any unresolved toxicity National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) grade >= 2 from previous anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the inclusion criteria * Patients with grade >= 2 neuropathy will be evaluated on a case-by-case basis after consultation with the study physician * Patients with irreversible toxicity not reasonably expected to be exacerbated by treatment with durvalumab or tremelimumab may be included only after consultation with the study physician
  • Major surgical procedure (as defined by the investigator) within 28 days prior to the first dose of the IP (investigational product, in this study, specifically durvalumab + tremelimumab combination). Note: local surgery of isolated lesions for palliative intent is acceptable
  • History of allogenic organ transplantation
  • Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease [e.g., colitis or Crohn's disease], diverticulitis, systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome [granulomatosis with polyangiitis], Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc]). The following are exceptions to this criterion: * Diverticulosis * Patients with vitiligo or alopecia * Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement * Any chronic skin condition that does not require systemic therapy * Patients without active disease in the last 5 years may be included but only after consultation with the study physician * Patients with celiac disease controlled by diet alone
  • Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring adverse events (AEs) or compromise the ability of the patient to give written informed consent
  • History of another primary malignancy except for * Malignancy treated with curative intent and with no known active disease >= 5 years before the first dose of the investigational product (IP) (durvalumab + tremelimumab combination) and of low potential risk for recurrence * Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease * Adequately treated carcinoma in situ without evidence of disease
  • History of leptomeningeal carcinomatosis
  • Patients with untreated brain metastases, spinal cord compression, or leptomeningeal carcinomatosis should be excluded from this clinical trial because of their poor prognosis, because of symptoms that may arise from inflammatory reactions, and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events. Patients whose brain metastases have been treated may participate provided they show radiographic stability (defined as 2 brain images, both of which are obtained after treatment to the brain metastases. These imaging scans should both be obtained at least four weeks apart and show no evidence of intracranial progression). In addition, any neurologic symptoms that developed either as a result of the brain metastases or their treatment must have resolved or be stable either, without the use of steroids, or are stable on a steroid dose of < 10 mg/day of prednisone or its equivalent and anti-convulsants for at least 14 days prior to the start of treatment
  • History of active primary immunodeficiency
  • Active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings, and tuberculosis [TB] testing in line with local practice), hepatitis B (known positive hepatitis B virus [HBV] surface antigen [HBsAg] result), hepatitis C, or human immunodeficiency virus (positive human immunodeficiency virus [HIV] 1/2 antibodies). Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody [anti-HBc] and absence of HBsAg) are eligible. Patients positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV ribonucleic acid (RNA)
  • Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab or tremelimumab. The following are exceptions to this criterion: * Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra articular injection) * Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or its equivalent * Steroids as premedication for hypersensitivity reactions (e.g., computed tomography [CT] scan premedication)
  • Mean QT interval corrected for heart rate (QTc) >= 470 ms on electrocardiogram (ECG)
  • Receipt of live attenuated vaccine within 30 days prior to the first dose of IP. Note: patients, if enrolled, should not receive live vaccine whilst receiving IP and up to 30 days after the last dose of IP
  • Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 90 days after the last dose of durvalumab monotherapy or 180 days after the last dose of durvalumab + tremelimumab combination therapy
  • Known allergy or hypersensitivity to any of the study drugs (durvalumab, tremelimumab) or any of the study drug excipients
  • Prior exposure to immune mediated therapy with anti-PD-1/ anti-PDL1 including durvalumab therapy, combined with an CTLA-4 therapy including tremelimumab

Locations & Contacts

Kentucky

Lexington
University of Kentucky / Markey Cancer Center
Status: Active
Contact: John Lee Villano
Phone: 859-323-8043
Email: jlvillano@uky.edu

Trial Objectives and Outline

PRIMARY OBJECTIVE:

I. To estimate the time-to-progression (TTP) ratio of somatically hypermutated recurrent/refractory solid tumor patients treated with MEDI4736 (durvalumab) and tremelimumab combination.

SECONDARY OBJECTIVES:

I. To evaluate duration of response, safety and toxicity, and response rate.

EXPLORATORY OBJECTIVES:

I. Correlative sciences will include liquid next generation sequencing (NGS) testing in all patients in order to analyze concordance of liquid and tumor biopsy (archival tissue) and to use immunohistochemistry to analyze PD-L1 expression by immunohistochemistry as well as infiltration of CD3+, CD4+, CD8+ T cells as a predictor of response to checkpoint blockade.

OUTLINE:

Patients receive tremelimumab intravenously (IV) over 60 minutes and durvalumab IV over 60 minutes every 4 weeks for up to 4 doses each (16 weeks). Beginning 4 weeks after the final dose of durvalumab in combination with tremelimumab, patients receive durvalumab IV over 60 minutes every 4 weeks for 2 years in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up for 2 years.

Trial Phase & Type

Trial Phase

Phase II

Trial Type

Treatment

Lead Organization

Lead Organization
University of Kentucky / Markey Cancer Center

Principal Investigator
John Lee Villano

Trial IDs

Primary ID MCC-18-MULTI-25-PMC
Secondary IDs NCI-2019-00665
Clinicaltrials.gov ID NCT03911557